Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025Frontiers in PharmacologyOpen Access

A systematic review and meta-analysis on the efficacy and safety of finerenone in the progression of heart failure

View Full Paper
Ask AI
Bookmark
Share

Authors

SPS. Andrew PengPLPeipei LiZYZhixi Yu

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis reveals finerenone may reduce heart failure risk in patients, suggesting safety but uncertain mortality impact.

Key Points

  • Finerenone significantly reduces heart failure occurrence and hospitalization risk compared to placebo, indicating potential efficacy.
  • Analysis of six randomized controlled trials with 21,295 participants reports a risk rate of 0.81 for heart failure progression.
  • The systematic review followed PRISMA guidelines, ensuring comprehensive and careful analysis of gathered data.
  • Balancing potential benefits against adverse effects is crucial, as doubts remain regarding overall mortality outcomes.

Cite This Study

Peng et al. (2025) studied this question.

synapsesocial.com/papers/68d41ed2713b0b5dfea67b08https://doi.org/10.3389/fphar.2025.1575307
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of Finerenone in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Trials2025
  2. 2Efficacy and Safety of Finerenone for Renal and Cardiovascular Events in DiabeticKidney Disease: A Meta-analysis2026
  3. 3Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial.2025
  4. 4Finerenone Versus Placebo on Renal Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review and Meta-Analysis2025 · 2 citations
  5. 5Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF2025